Angle PLC Announces HER2 Presentation at SABCS

Rhea-AI Summary

ANGLE plc announced the presentation of an independent study by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, showcasing a novel Parsortix-based HER2 workflow. The study, involving 16 metastatic breast cancer patients, demonstrated 100% success in isolating CTCs and classifying their HER2 status. The research identified patients with HER2-expressing CTCs who had HER2-negative tissue biopsies, suggesting potential for expanded treatment options.

The workflow enables quantitative and semi-automated assessment of HER2 in CTCs, which is important as HER2 status can change in up to 38% of breast cancer patients. This development could help identify patients eligible for HER2-targeted antibody drug conjugates (ADCs), particularly beneficial for the over 60% of breast cancer patients initially diagnosed as HER2-negative.

Positive

• 100% success rate in CTC isolation and HER2 classification in study patients
• Potential to identify additional patients eligible for HER2 targeted treatments
• Semi-automated solution that could accelerate adoption of CTC-based HER2 tests
• Independent validation of ANGLE's HER2 assay development programme

Negative

• None.

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM

Independent findings support ANGLE's HER2 assay development programme

Potential for stratification of breast cancer patients for treatment with HER2 antibody drug conjugates

SURREY, UK / ACCESSWIRE / December 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of an independent study, reporting on a novel, Parsortix^®-based human epidermal growth factor receptor 2 (HER2) workflow at the prominent San Antonio Breast Cancer Symposium being held from 10 to 13 December 2024.

The findings, published by Weill Cornell Medicine, corroborate ANGLE's own findings from its HER2 assay development programme, and provide a semi-automated solution which may help to accelerate adoption of CTC-based HER2 tests. HER2 status is known to change in a significant proportion of breast cancer patients over time, so a minimally invasive, real-time assay is needed for dynamic HER2 assessment to enable targeted treatment selection and detection of emerging treatment resistance or progression.

HER2 is a protein that is associated with many cancers, and HER2 tumour marker testing is used to determine if targeted therapy will be effective. A quantitative HER2 test, that objectively measures HER2 expression levels, enables the identification of patients who are HER2-high, intermediate or low and therefore suitable for treatment with HER2-antibody drug conjugates (ADCs).

The poster reports on a study in 16 patients with metastatic breast cancer, in which the Parsortix system was used to isolate and harvest CTCs and CTC-clusters prior to automated imaging and classification as HER2-high, intermediate, low or negative. Using the Parsortix system, CTCs were identified in 100% of patients and their HER2 status classified. Importantly the study identified patients with HER2 expressing CTCs that had a HER2-negative tissue biopsy.

Over 60% of breast cancer patients have a HER2-negative tissue biopsy when diagnosed and, as a result, are currently excluded from prescription of HER2 targeted ADCs. The workflow presented in this poster has the potential to be used to assess the current HER2 status of these patients and identify those whose HER2 status has changed making them eligible for the treatment.

Dr. Carolina Reduzzi, Assistant Professor of Cancer Biology Research in Medicine, Weill Cornell Medicine commented:
"We are pleased to present further data validating our workflow which enables quantitative and semi-automated assessment of HER2 in CTCs. HER2 is a major therapeutic target and an accurate and real-time assessment of HER2 status could be used to monitor CTCs over time to better guide treatment and identify patients with any detectable HER2 expression, or changes to HER2 expression, who could benefit from treatment with ADCs.

This methodology has the potential to be applied to a wide range of biomarkers and our ultimate goal is to develop automated workflows which enable longitudinal CTC assessment of biomarker status for targeted treatment selection or to predict treatment response."

ANGLE's Chief Scientific Officer, Karen Miller, commented:
"We are pleased to see new data that supports the utility of quantitative HER2 assessment on CTCs isolated using the Parsortix system and independently validates ANGLE's own findings from our HER2 assay development programme. HER2 status is known to change in up to 38% of breast cancer patients. As such real-time quantitative HER2 assessment is crucial for both effective treatment and to support patient stratification for clinical trials and insight into dynamic changes in HER2 status which may correlate to therapeutic response."

The poster is available at: https://angleplc.com/resources/posters/

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	+44 (0) 20 3207 7800
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:

The Parsortix^® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K₂EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on accesswire.com

FAQ

What were the key findings of ANPCY's HER2 Parsortix study at SABCS 2024?

The study showed 100% success in isolating CTCs and classifying HER2 status in 16 metastatic breast cancer patients, identifying HER2-expressing CTCs in patients with HER2-negative tissue biopsies.

How could ANPCY's Parsortix HER2 workflow benefit breast cancer patients?

The workflow could help identify patients whose HER2 status has changed, potentially making them eligible for HER2-targeted treatments, particularly beneficial for the 60% of patients initially diagnosed as HER2-negative.

What percentage of breast cancer patients could benefit from ANPCY's HER2 testing?

Over 60% of breast cancer patients who are initially diagnosed as HER2-negative could potentially benefit from this testing, as HER2 status can change in up to 38% of patients.

How does ANPCY's Parsortix system assess HER2 status in cancer patients?

The Parsortix system isolates and harvests CTCs and CTC-clusters, followed by automated imaging and classification of HER2 status as high, intermediate, low, or negative.